What's new in atrial fibrillation?

CPD QUESTIONNAIRE

EARN FREE CPD POINTS

Complete, scan and email to **cpd@denovomedica.com**. Alternatively, you can complete this questionnaire online at **www.denovomedica.com**. Fill in your details using **clear block letters** and mark the answers with a tick (✓).

I agree that my CPD-accredited certificate will be forwarded to my e-mail address. (Online) _____

(Signature of healthcare professional)

First Name		**Profession**	
Surname		**Telephone**	
HPC No.		**City**	
E-mail			

1. Dabigatran therapy with a 150mg dose bid in AF patients was shown to be safe and effective with a hazard ratio of:

☐ **A** 0.65 ☐ **B** 0.85 ☐ **C** 1.01

2. In the RE-LY study, what percentage of patients was given a standard dose (150mg bid) as compared to a reduced dose (110mg bid)?

☐ **A** 50% ☐ **B** 55% ☐ **C** 65%

3. In real-world patients, a dabigatran standard dose as compared to a low dose closely reflects what was seen in the RE-LY cohort.

☐ **A** True ☐ **B** False

4. In real-world patients, use of FXa inhibitors such as rivaroxaban closely reflects what was seen in the relevant phase III trial.

☐ **A** True ☐ **B** False

5. Real-world registries such as GLORIA-AF closely mimic actual phase III trials except that:

☐ **A** Patients are older than in the clinical trials ☐ **B** Patients are sicker ☐ **C** Patients are healthier

6. In the real world internationally, what percentage of AF patients are still taking their medication after two years?

☐ **A** 20% ☐ **B** 30% ☐ **C** 40% ☐ **D** 50%

7. When performing ablation in dabigatran-treated AF patients, anticoagulant therapy should be:

☐ **A** Discontinued for 24 hours prior to ablation ☐ **B** Discontinued 12 hours before ablation ☐ **C** Continued during ablation

8. The incidence of major bleeding events on dabigatran versus warfarin treatment during and up to eight weeks post-ablation was:

☐ **A** Reduced ☐ **B** Increased ☐ **C** Remained the same

9. In the RE-DUAL PCI trial, dual antithrombotic therapy with dabigatran plus a $P2Y_{12}$ inhibitor reduced the risk of bleeding compared to triple therapy with warfarin, a $P2Y_{12}$ inhibitor and aspirin.

☐ **A** True ☐ **B** False

10. In the RE-DUAL PCI trial intracranial haemorrhage occurred in what percentage of patients treated with dual therapy (dabigatran 150mg plus $P2Y_{12}$ inhibitor)?

☐ **A** 0.1% ☐ **B** 0.2% ☐ **C** 0.3%

11. The incidence of major bleeding on DOAC therapy that requires a reversal agent in the view of attending clinician is on average:

☐ **A** 0.6-1% ☐ **B** 1-2% ☐ **C** 2-3%

12. Idarucizumab was registered in South Africa as the reversal agent for dabigatran in:

☐ **A** 2018 ☐ **B** 2019 ☐ **C** 2020

13. Which of the following statements is false?

☐ **A** Idarucizumab was specifically designed as a reversal agent for dabigatran
☐ **B** Idarucizumab binds irreversibly to dabigatran
☐ **C** Idarucizumab has a procoagulant action
☐ **D** The idarucizumab-dabigatran complex is eliminated within a few hours

14. Andexanet alfa, as a decoy factor X, has been approved in the USA and Europe as a reversal agent in patients treated with:

☐ **A** Apixaban or rivaroxaban ☐ **B** Enoxaparin

15. Which statement is false?

☐ **A** Idarucizumab is given in a standard dose of 5g, consisting of two 2.5g vials
☐ **B** Idarucizumab needs to be adjusted for different age groups
☐ **C** Idarucizumab achieves sustained reversal of dabigatran

© 2020 deNovo Medica